Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | PLAT | P00750 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 3/20 | 0.34 |
| ▸ | GABRD | O14764 | 3/20 | 0.34 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.34 |
| ▸ | GABRB1 | P18505 | 3/20 | 0.34 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.34 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.34 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.34 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.34 |
| ▸ | GABRA4 | P48169 | 3/20 | 0.34 |
| ▸ | GABRE | P78334 | 3/20 | 0.34 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.34 |
| ▸ | GABRG1 | Q8N1C3 | 3/20 | 0.34 |
| ▸ | GABRG3 | Q99928 | 3/20 | 0.34 |
| ▸ | GABRQ | Q9UN88 | 3/20 | 0.34 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL850863 | 0.81 | PLG (0.38) | PLGPLATLMNAGABRPGABRD | |
| SCHEMBL850840 | 0.81 | GAA (0.37) | PLGPLATLMNAGABRPGABRD | |
| SCHEMBL10636223 | 0.79 | ESR2 (0.44) | PLGPLATLMNAGABRPGABRD | |
| SCHEMBL13279903 | 0.71 | GABRP (0.41) | PLGPLATLMNAGABRPGABRD | |
| SCHEMBL7095734 | 0.71 | GABRP (0.45) | PLGPLATLMNAGABRPGABRD | |
| SCHEMBL28822241 | 0.70 | GABRP (0.40) | PLGPLATLMNAGABRPGABRD | |
| SCHEMBL7080330 | 0.70 | TSHR (0.44) | PLGPLATLMNAGABRPGABRD | |
| SCHEMBL28119613 | 0.68 | GABRP (0.38) | PLGPLATLMNAGABRPGABRD | |
| SCHEMBL12968303 | 0.64 | GABRP (0.36) | PLGPLATLMNAGABRPGABRD | |
| SCHEMBL27041262 | 0.64 | GABRP (0.46) | PLGPLATLMNAGABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487517-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2433940-B9 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-9169254-B2 | Spiroimidazolone derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-10-27 | — | — | US | disclosed |
| EP-2433940-B1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| EP-2433940-A1 | SPIROIMIDAZOLONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | PLG 4622/4885PLAT 4405/4885LMNA 2006/4885 |
| US-20160016956-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | PLG 4622/4885PLAT 4405/4885LMNA 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.